Galera Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of therapeutics that have the potential to transform radiotherapy in cancer. Co. utilizes its capabilities in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Co.'s product candidate, avasopasem manganese, GC4419, is a selective small molecule dismutase mimetic that is developing for the reduction of severe oral mucositis. Co.'s another dismutase mimetic product candidate, GC4711, is to increase the anti-cancer efficacy of stereotactic body radiation therapy. We show 20 historical shares outstanding datapoints in our GRTX shares outstanding history coverage, used to compute GRTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GRTX market cap history over the course of time is important for investors
interested in comparing GRTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GRTX versus a peer is one thing; comparing
GRTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GRTX can fluctuate over the course of history.
With this page we aim to empower investors researching GRTX by allowing them to research the GRTX market cap history. |
Free GRTX Email Alerts:
Video: The Importance of Market Cap
